Sarah Cannon, the global cancer institute of Hospital Corporation of America (HCA), and HCA Midwest Health, Kansas City’s largest healthcare network, announced today that they have expanded their cancer collaboration through clinical research. By joining a global research network, HCA Midwest Health is offering greater access to clinical trials for those facing cancer in the Kansas City region.
“Clinical trials are an integral part of advancing the standard of cancer care, as today’s trials are tomorrow’s cutting-edge treatments,” said Howard A. "Skip" Burris, III, MD, President of Clinical Operations and Chief Medical Officer at Sarah Cannon. “By expanding our collaboration, we can provide patients in Kansas City access to the latest therapies with the comfort of their physicians, family and friends close to home.”
Patients can access clinical trials throughout the entire HCA Midwest Health system. The initial strategic research sites where Sarah Cannon clinical trials will be conducted in the coming weeks include Menorah Medical Center and Research Medical Center, with additional HCA Midwest Health sites planned to launch in the near future. With expert investigators who specialize in several areas of cancer including medical oncology, hematology, gynecology and neuro-oncology, Sarah Cannon Research Institute at HCA Midwest Health has the capabilities and experience to conduct a wide variety of clinical trials.
Since 2014, HCA Midwest Health and Sarah Cannon have worked together to advance cancer services in Kansas City. Sarah Cannon Research Institute at HCA Midwest Health will be supported and complemented by the system’s seven hospitals, Belton Regional Medical Center, Centerpoint Medical Center, Lafayette Regional Health Center, Lee's Summit Medical Center, Menorah Medical Center, Overland Park Regional Medical Center and Research Medical Center and numerous cancer care outreach sites located in communities throughout the region.
“Sarah Cannon is at the forefront of international cancer research, leading studies for approximately 80 percent of approved therapies over the last decade,” said Jaswinder Singh, MD, Medical Director, Clinical Research, Sarah Cannon at HCA Midwest Health. “HCA Midwest Health has long been recognized for our strong physician leadership and clinical excellence in cancer care delivery. By working with a global network of experts, we can offer our patients seeking new treatment options even greater access to potentially life-saving therapies in our communities.”
Sarah Cannon Research Institute is the arm of Sarah Cannon that conducts over 500 community-based trials through affiliations with 1,000+ physicians across the United States and United Kingdom. Through its research program, Sarah Cannon enrolls more than 2,000 cancer patients to studies annually.
See more coverage: